Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT06707025
Active, not recruiting Observational

The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma

NCT06707025 · tracked via the Priya Life Science Israel tracker
Sponsor
Hadassah Medical Organization
Phase
Observational
Started
2023-11-10
Last updated
2025-03-14

Condition(s) studied

Cholangiocarcinoma

Study summary

The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice. the investigators are interested in confirming this result in humans. Details of the preliminary results are attached to the submission of the research documents. the investigators will compare Cholangiocarcinoma tumors with other solid tumors, including liver tissue. The need to deepen understanding the investigators will also make a comparison between cancerous tissue and "normal" tissue adjacent to the tumor.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: \* Donors with cholangiocarcinoma samples Exclusion Criteria: \* Donors who do not have cholangiocarcinoma samples

Primary outcome measure(s)

  • the investigators will analyze ductular reaction and cancer stem cells markers including CD24, CD44 — All along the study, from the first recruitment to the last recruitment. average of 1 year
    the investigators will perform the analysis on tissue samples of cholangiocarcinoma and non tumor controls, using immunohistochemistry and RT-PCR

Trial sites (1)

FacilityCityRegionStatus
Hdassah Hospital Jerusalem Israel

More Hadassah Medical Organization trials in Israel

Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects Starting soon
The Computerized Retraining and Functional Treatment - Group Intervention Recruiting
Testis Needle Aspiration of Sperm in Men With Azoospermia Recruiting
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis Active, not recruiting
Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence Recruiting

Other trials for the same condition

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06707025 on ClinicalTrials.gov ↗ ← All trials in Israel